Academisch Medisch Centrum — Clinical Trial Site

86 Registered trials

30 Currently recruiting

Organisation

Academisch Medisch Centrum

Location

Amsterdam, Netherlands

Identifier

ORG-100006320

Address

Meibergdreef 9, 1105 AZ, Netherlands

Departments

(Pediatric) Neurology
#1500:Dept. of Hematology
#1700: Heart center, department of cardiology
#3701: Cardiology
#NDL1 Pharmacy
2500: Hematology
3701: Cardiology
Academisch Medisch Centrum
AMC
Amsterdam UMC, Locatie AMC (#1)
Amsterdam Universitair Medische Centra(#1)
Cardiology
Child Neurology, Neurology and Paediatrics
Children's nephrology
Clinical Hematology Department
Department of Gastroenterology & Hepatology (MDL)
Department of Hematology
Department of Intensive Care Medicine
Department of Medical Oncology
Department of Neurolog
Department of Oncology
Department of Ophthalmology
Department of Pulmonology
Department of Vascular Medicine
Dermatology
Gastroenterology
Gastrointestinal tract
Gynaecology
Hematologie (AMC)
Hematology
Infectious Diseases
Internal and Vascular Medicine & Haemophilia
Internal Medicine / Dialysis
MDL
Medical Oncology
Medische Oncologie
metabole ziekten
N/A
NA
Nephrology
Neurology
Neurosurgery
Oncology
Paediatric Gastroenterology
Paediatrics
Parent
Pulmonary Science
Rheumatology
Rheumatology and Clinical Immunology
Surgery
Urology
Vascular medicine
Vascular Medicine Clin Trial Unit

Clinical trials at this site (86)

Search interface

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended

2023-503813-31-01 Second- or Third-Line Recurrent or Metastatic Cervical 5 2021-09-17
Long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks Ended

2024-510777-18-00 Hereditary angioedema 5 2021-06-15
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult pat… Ended

2024-512603-39-00 Haemophilia B 7 2021-01-08
Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended

2023-503956-29-00 Microsatellite Instability High (MSI-H) or Mismatch Rep 5 2019-08-26
Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma Ended

2023-508127-13-00 Adult patients with refractory or relapsed follicular l 4 2019-01-25
A phase III trial investigating a gene therapy (AAV-hFIXco-Padua, AMT061), in adult patients with severe or moderately severe haemophilia B,… Ended

2024-510738-42-00 Haemophilia B 5 2018-12-03
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended

2023-506641-35-00 Relapsed/Refractory Mantle Cell Lymphoma 4 2018-07-09
A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treat… Ended

2024-510634-41-00 Recurrent, metastatic, or persistent Cervical Carcinoma 4 2018-02-22
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who… Ended

2023-510557-42-00 chronic lymphocytic leukemia 4 2017-07-10
GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended

2024-511048-22-00 Chronic lymphocytic leukemia 4 2016-10-27
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants Wi… Ended

2024-510727-19-00 Crohn's Disease (CD) 4 2016-10-11
CheckMate 274 Ended

2022-500630-29-00 Subjects with High Risk Invasive Urothelial Carcinoma 5 2016-05-06
A study evaluating the safety, tolerability, and efficacy of GLPG5101 in adults with treatment-refractory active systemic lupus erythematosu… Ended

2023-504422-19-00 Treatment-refractory active systemic lupus erythematosu 3